These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 1892748

  • 41. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs.
    Jansen BA, Brouwer J, Reedijk J.
    J Inorg Biochem; 2002 Apr 28; 89(3-4):197-202. PubMed ID: 12062123
    [Abstract] [Full Text] [Related]

  • 42. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
    Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR.
    Br J Cancer; 1992 Dec 28; 66(6):1109-15. PubMed ID: 1457352
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G, Zeller WJ.
    Anticancer Res; 1991 Dec 28; 11(6):2231-7. PubMed ID: 1776864
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
    Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF.
    Biochem Pharmacol; 1985 Jul 15; 34(14):2583-6. PubMed ID: 4040369
    [No Abstract] [Full Text] [Related]

  • 47. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
    Hansson J, Edgren M, Ehrsson H, Ringborg U, Nilsson B.
    Cancer Res; 1988 Jan 01; 48(1):19-26. PubMed ID: 3334994
    [Abstract] [Full Text] [Related]

  • 48. Differential properties of cisplatin and tetraplatin with respect to cytotoxicity and perturbation of cellular glutathione levels.
    Müller MR, Wright KA, Twentyman PR.
    Cancer Chemother Pharmacol; 1991 Jan 01; 28(4):273-6. PubMed ID: 1879044
    [Abstract] [Full Text] [Related]

  • 49. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR.
    Cancer Res; 1992 Apr 01; 52(7):1710-6. PubMed ID: 1312897
    [Abstract] [Full Text] [Related]

  • 50. Effect of glutathione-modulating compounds on platinum compounds-induced cytotoxicity in human glioma cell lines.
    Iida M, Doi H, Asamoto S, Sugiyama H, Sakagami H, Kuribayashi N, Takeda M, Okamura Y, Matsumoto K.
    Anticancer Res; 1999 Apr 01; 19(6B):5383-4. PubMed ID: 10697565
    [Abstract] [Full Text] [Related]

  • 51. A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines.
    Rhodes T, Twentyman PR.
    Br J Cancer; 1992 May 01; 65(5):684-90. PubMed ID: 1316774
    [Abstract] [Full Text] [Related]

  • 52. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
    Peters RH, Jollow DJ, Stuart RK.
    Cancer Res; 1991 May 15; 51(10):2536-41. PubMed ID: 2021933
    [Abstract] [Full Text] [Related]

  • 53. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note.
    Goddard PM, Valenti MR, Harrap KR.
    Ann Oncol; 1991 Sep 15; 2(8):535-40. PubMed ID: 1793720
    [Abstract] [Full Text] [Related]

  • 54. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms.
    Zhang K, Chew M, Yang EB, Wong KP, Mack P.
    Mol Pharmacol; 2001 Apr 15; 59(4):837-43. PubMed ID: 11259628
    [Abstract] [Full Text] [Related]

  • 55. Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion.
    Andrews PA, Murphy MP, Howell SB.
    Mol Pharmacol; 1986 Dec 15; 30(6):643-50. PubMed ID: 3785141
    [Abstract] [Full Text] [Related]

  • 56. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
    Meijer C, Mulder NH, Hospers GA, Uges DR, de Vries EG.
    Br J Cancer; 1990 Jul 15; 62(1):72-7. PubMed ID: 2390486
    [Abstract] [Full Text] [Related]

  • 57. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
    Misawa T, Kikkawa F, Maeda O, Obata NH, Higashide K, Suganuma N, Tomoda Y.
    Jpn J Cancer Res; 1995 Jan 15; 86(1):88-94. PubMed ID: 7737915
    [Abstract] [Full Text] [Related]

  • 58. Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.
    Canada A, Herman L, Kidd K, Robertson C, Trump D.
    Cancer Chemother Pharmacol; 1993 Jan 15; 32(1):73-7. PubMed ID: 8462127
    [Abstract] [Full Text] [Related]

  • 59. Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines.
    Mans DR, Schuurhuis GJ, Treskes M, Lafleur MV, Retèl J, Pinedo HM, Lankelma J.
    Eur J Cancer; 1992 Jan 15; 28A(8-9):1447-52. PubMed ID: 1325177
    [Abstract] [Full Text] [Related]

  • 60. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion.
    Andrews PA, Schiefer MA, Murphy MP, Howell SB.
    Chem Biol Interact; 1988 Jan 15; 65(1):51-8. PubMed ID: 3345573
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.